CRN00808

DRUG2 trials

Sponsors

Crinetics Pharmaceuticals Inc.

Conditions

Healthy Volunteers

Phase 1

Single and Multiple-Ascending Dose Study of CRN00808 in Healthy Volunteers

CompletedNCT03276858

Crinetics Pharmaceuticals Inc.Healthy Volunteers

Start: 2017-09-22End: 2018-04-30Updated: 2018-08-29

Mass Balance and Pharmacokinetics of [14C]-CRN00808 in Healthy Volunteers

CompletedNCT04246749

Crinetics Pharmaceuticals Inc.Healthy Volunteers

Start: 2019-09-17End: 2019-10-25Updated: 2020-01-29

Related Papers

Paltusotine, a novel oral once-daily nonpeptide SST2 receptor agonist, suppresses GH and IGF-1 in healthy volunteers.

2022-01-0923 citations

SAT-429 Final Results from the First in Man Phase 1 Clinical Trial of CRN00808, an Orally Bioavailable sst2-Selective, Nonpeptide Somatostatin Biased Agonist, for the Treatment of Acromegaly: Safety, Pharmacokinetics, Pharmacodynamics, and Midazolam Drug Interaction in Healthy Volunteers

Journal of the Endocrine Society2019-04-018 citations